Concepedia

Author

Madoka Shiino

Takeda (Japan)

Also Known As

Madoka Shiino

8

Publications

625

Citations

6

H-Index

11

Concepts

All Affiliations

Takeda (Japan)Rakuwakai Otowa HospitalKobe UniversityNippon Medical School
MS

About

Madoka Shiino is an author at Takeda (Japan) specializing in antibiotics, pharmacotherapy, and medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

53

2

Pharmacology

2

2

53

3

Antibiotics

2

2

53

4

Health Sciences

1

1

13

5

Antimicrobial Pharmacokinetics

1

1

40

Madoka Shiino

×

6

Publications

623

Citations

6

H-Index

YearCitations

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for <i>Helicobacter pylori</i> eradication: a phase III, randomised, double-blind study

Kazunari Murakami, Yuuichi Sakurai, Madoka Shiino,

Gut

2016

420

Evaluation of the Efficacy and Safety of Vonoprazan in Patients with Nonerosive Gastroesophageal Reflux Disease: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study

Yoshikazu Kinoshita, Yuuichi Sakurai, Madoka Shiino,

Current Therapeutic Research

2016

71

A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis

Katsuhiko Iwakiri, Yuuichi Sakurai, Madoka Shiino,

Therapeutic Advances in Gastroenterology

2017

62

Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized, Crossover Study

Yuuichi Sakurai, Madoka Shiino, Hiroyuki Okamoto,

Advances in Therapy

2016

40

Pharmacokinetic Drug–Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese Men

Yuuichi Sakurai, Madoka Shiino, Sayako Horii,

Clinical Drug Investigation

2016

17

Tu1056 A Phase 3, Double-Blind Study of a Triple Therapy With TAK-438, Amoxicillin, and Clarithromycin As First Line Eradication of H. pylori and a Triple Therapy With TAK-438, Amoxicillin, and Metronidazole As Second Line Eradication of H. pylori

Kazunari Murakami, Yuuichi Sakurai, Madoka Shiino,

Gastroenterology

2014

13

Page 1